After 24 weeks , statin use slowed mean eGFRcr decline ( 1.61 vs -3.08 mL/minute/1 .73 m ( 2 ) for statin vs placebo ; P = .033 ) and decreased mean cystatin C ( -0.034 mg/L vs 0.010 mg/L ; P = .008 ) .